---
search:
  boost: 3
---

# Benign Prostatic Hyperplasia

This is a subcategory of Genitourinary Agents.

## Decision Trees

- [Genitourinary - Benign Prostatic Hyperplasia- Non-Preferred Products](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNDhQUkMyNUdBTVNBN0FGUkhYMURDR1UyQSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Genitourinary - Benign Prostatic Hyperplasia- Non-Preferred- Dutasteride/Tamsulosin](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQklRWUMzMFFFQkM4VzE4Q1hBSzlZU1NDWCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Genitourinary - Benign Prostatic Hyperplasia - Tadalafil 2.5mg, 5mg](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNUs2SzRXTU9MTVhSVjc4NDdPNVRYQUJCNiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                         | Generic Name | Quantity | Time (Days) |
|:----------------------------------|:-------------|:--------:|:-----------:|
| Alfuzosin                         |              |          |             |
| Doxazosin                         |              |          |             |
| Dutasteride                       |              |          |             |
| Finasteride                       |              |          |             |
| Prazosin                          |              |          |             |
| Tadalafil <sup>PA</sup> 2.5, 5 MG |              |          |             |
| Tamsulosin                        |              |          |             |
| Terazosin                         |              |          |             |

### Non-Preferred

| Non-Preferred            | Generic Name | Quantity | Time (Days) |
|:-------------------------|:-------------|:--------:|:-----------:|
| Cardura XL               |              |          |             |
| Dutasteride / Tamsulosin |              |          |             |
| Entadfi                  |              |          |             |
| Silodosin                |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Tadalafil (Cialis)

Tadalafil (Cialis) Criteria

- Must have had an inadequate clinical response of at least **30 days** with at least **one** alpha-1 adrenergic blocker. If prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE), then a trial of at least ^^90 days^^ of finasteride is required.

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Dutasteride / Tamsulosin (Jalyn) & Finasteride / Tadalafil (Entadfi)

Additional Dutasteride / Tamsulosin (Jalyn) & Finasteride / Tadalafil (Entadfi) Criteria

- Must provide documentation for patientâ€™s inability to use the individual drugs

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=66&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"}

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=72){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=25){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
